Veeda Clinical Research unlisted share price

Price history

About

Veeda Clinical Research Limited is a contract research organisation, or CRO, headquartered in Ahmedabad, Gujarat. In simple words, drug companies pay it to test their medicines. Its work covers human clinical trials and the testing of drugs and medicines against standards such as IP, USP and BP. The company says it carries out clinical research under international guidelines such as DCGI, USFDA, ICH ANVISA and MHRA. In FY26 the group started using the brand name Veeda Lifesciences. The group has grown through acquisitions. Its subsidiaries include Bioneeds India Private Limited (91% held), Ingenuity Biosciences Private Limited and Veeda Clinical Research Ireland Limited. Through Health Data Specialists and Heads Research AG it also has step down companies in Europe, the USA and Australia. This gives it a large overseas revenue base. In FY26 the standalone company earned foreign exchange of INR 3,378.48 million. On a consolidated basis, revenue from operations was INR 7,154.92 million in FY26, against INR 6,097.26 million in FY25. Profit before interest, depreciation, amortisation and tax was INR 2,262.93 million. Depreciation of INR 1,569.41 million and interest of INR 620.27 million took most of it away, so the group reported a loss for the year of INR 139.98 million, narrower than the loss of INR 668.11 million in FY25. On a standalone basis, revenue was INR 3,097.23 million and profit was INR 80.59 million, after an exceptional item of INR 241.60 million. The annual report shows the company had 69858503 fully paid equity shares of face value ₹2 each on 31 March 2026. It issued 4081008 of these during the year to existing shareholders in exchange for their preference shares of its Irish subsidiary. Binoy Hasmukh Gardi became Managing Director and Group CEO in January 2026, after Dr. Mahesh Kantilal Bhalgat resigned. Shareholders approved this at the meeting of 23 March 2026. On the IPO front, the company filed a draft red herring prospectus with SEBI on 31 January 2025. Its board decided on 2 February 2026 to withdraw it and informed SEBI, BSE and NSE. No new filing is shown in the report. Unlisted shares of a company like this trade off-market between private buyers and sellers, not on an exchange. Prices are indicative and can differ from deal to deal. IPO Guru shows an indicative price of ₹428 per share with a lot size of 100 shares, which implies a market cap of about ₹2,989.94 crore on the share count above.